0025Reducing Gaps in Cardiovascular Risk Factor Awareness through Free At-Home LDL-C and Lipoprotein(a) Screening and Support: Insights from the First 30,950 Tests Ordered through the Family Heart Foundation Cholesterol Connect® Program

Background LDL cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are independent risk factors for cardiovascular disease (CVD). LDL-C and Lp(a) healthcare screening is inconsistent, leaving many Americans at risk. The Family Heart Foundation® launched the Cholesterol Connect® program in September 2024 -providing free, at-home screening of LDL-C and Lp(a) with Care Navigator support- to increase awareness and encourage reduction of cholesterol-related CVD risks. Objectives Characterize Cholesterol Connect screening order follow-through, engagement, and satisfaction. Methods Dispensed kits were tracked from September 2024 to March 2026 to determine number resulted and number of results indicating levels of LDL-C >100 mg/dL and/or Lp(a) >125 nmol/L. Adults with elevated levels received email invitations to engage with Care Navigation. User satisfaction was quantified using the Net Promoter Score (NPS), calculated from surveying individuals who returned kits between March 2025 to March 2026 (n=5300). Results Kit orders (n=30,950) exceeded projections (Figure 1) and 8,675 (28%) were returned and completed with results. The majority (65%) of kit results revealed a cholesterol-related cardiovascular risk (Figure 2); 24% revealed elevated Lp(a) and 54% had LDL-C>100mg/dL. Of individuals with high results, 15% engaged with one-on-one Care Navigation support. NPS was 73.8 (considered excellent, industry benchmarks range from -10 to 19). Respondents appreciated the valuable health information, simple process, and access without cost. Conclusion The Family Heart Foundation’s Cholesterol Connect program has identified 5,629 screening results demonstrating high LDL-C and/or Lp(a) levels, increasing risk awareness and motivating individuals to address risks. Satisfaction with the program greatly surpasses relevant benchmarks. Strategies to further improve kit return rates are underway. Is this an encore abstract? No